Clinical trial
Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's…
NCT00002445 · Cytran, Industry · Completed
Key facts
| NCT number | NCT00002445 |
|---|---|
| Title | Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients |
| Official title | A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma |
| Lead sponsor | Cytran, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sarcoma, Kaposi, HIV Infections |
| Intervention type | Drug |
| Interventions | IM862 |
| Enrollment | 200 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Australia, Belgium, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: